Samsung Electronics Co.'s research and development (R&D) spending for the first nine months of the year hit a record high of 15.89 trillion won, representing a 600 billion-won increase from a year earlier.
It was also over 5 trillion won from its R&D investment tally in the first half of the year.
Samsung's investment in research has been consistently increasing since 2017 when it spent 16.8 trillion won, to 2018 when it allocated 18.7 trillion won, and in 2019 when it spent 20.2 trillion won.
In the third quarter, the South Korean tech giant registered 4,974 patents locally and 6,321 patents in the US.
It has registered 194,643 patents globally, with 77,016 patents of those in the US.
Samsung's capital expenditure is expected to reach 35.2 trillion won this year, the first time since 2017 to surpass the 30-trillion won mark.
In the first nine months, its capital expenditure reached 25.5 trillion won, up 52 percent from the same period last year.


Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 



